peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

metabolic hormone

Adiponectin

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

Adiponectin is classified as an adipokine and is secreted by adipocytes, indicating adipose tissue is its primary source. This defines the outcome grouping used for analysis; it does not indicate that adiponectin changes outcomes. Despite biomarker potential, the abstract states adiponectin is not sufficient to substitute for OGTT as a diagnostic standard for GDM.

Sources for this introduction: [1] [2] [3]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Adiponectin is classified as an adipokine and is secreted by adipocytes, indicating adipose tissue is its primary source.

Sources[1]iuphar-ligandadiponectinName: adiponectin Ligand ID: 3726 Type: Peptide[4]pubmedThe effect of ascorbic acid supplementation on plasma leptin and adiponectin levels: Systematic review ofin vivoandin vitrostudies.Adiponectin, an adipokine released by adipocytes[4]pubmedThe effect of ascorbic acid supplementation on plasma leptin and adiponectin levels: Systematic review ofin vivoandin vitrostudies.Adiponectin, an adipokine released by adipocytes, is recognized as an important factor in maintaining balance of blood glucose levels, lipid metabolism and insulin sensitivity.
Source records
3
Independent studies
2

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Name: adiponectin Ligand ID: 3726 Type: Peptide”

    adiponectin · Identity and approval

    iuphar-ligand:3726:0853cb8a8851:0853cb8a8851
  2. supports · Source-backed record
    “Adiponectin, an adipokine released by adipocytes”

    The effect of ascorbic acid supplementation on plasma leptin and adiponectin levels: Systematic review ofin vivoandin vitrostudies. · BACKGROUND

    pubmed:42592588:78c8d937b998:78c8d937b998
  3. supports · Source-backed record
    “Adiponectin, an adipokine released by adipocytes, is recognized as an important factor in maintaining balance of blood glucose levels, lipid metabolism and insulin sensitivity.”

    The effect of ascorbic acid supplementation on plasma leptin and adiponectin levels: Systematic review ofin vivoandin vitrostudies. · BACKGROUND

    pubmed:42592588:78c8d937b998:78c8d937b998

How does it work?

Target, response, and disposition.

Mechanism

This prospective cohort evaluated gestational serum adiponectin (APN) as an exposure variable and postpartum glycaemic outcomes as endpoints in women with GDM.

Sources[2]pubmedAssociation of gestational serum adiponectin with postpartum glycaemic outcomes in GDM: a prospective cohort study.This study investigated the association between gestational serum adiponectin (APN) levels and postpartum glycaemic outcomes in women with gestational diabetes mellitus (GDM).
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “This study investigated the association between gestational serum adiponectin (APN) levels and postpartum glycaemic outcomes in women with gestational diabetes mellitus (GDM).”

    Association of gestational serum adiponectin with postpartum glycaemic outcomes in GDM: a prospective cohort study. · BACKGROUND

    pubmed:42029679:000ef5d270f6:000ef5d270f6

Mechanism

This defines the outcome grouping used for analysis; it does not indicate that adiponectin changes outcomes.

Sources[2]pubmedAssociation of gestational serum adiponectin with postpartum glycaemic outcomes in GDM: a prospective cohort study.Based on 1-year follow-up data, patients were classified into favourable (normal glucose metabolism) and unfavourable (prediabetes or type 2 diabetes mellitus [T2DM]) outcome groups.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Based on 1-year follow-up data, patients were classified into favourable (normal glucose metabolism) and unfavourable (prediabetes or type 2 diabetes mellitus [T2DM]) outcome groups.”

    Association of gestational serum adiponectin with postpartum glycaemic outcomes in GDM: a prospective cohort study. · METHODS

    pubmed:42029679:000ef5d270f6:000ef5d270f6

What has been studied?

What the evidence says.

Comparative evidence

Despite biomarker potential, the abstract states adiponectin is not sufficient to substitute for OGTT as a diagnostic standard for GDM.

Sources[3]pubmedRole of adiponectin in gestational diabetes mellitus: advances in mechanistic insights and early predictive potential.however, adiponectin cannot replace OGTT as a diagnostic criterion.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “however, adiponectin cannot replace OGTT as a diagnostic criterion.”

    Role of adiponectin in gestational diabetes mellitus: advances in mechanistic insights and early predictive potential. · Abstract

    pubmed:42516090:62ad3bdeedf2:62ad3bdeedf2

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, interaction, regulatory, safety
  • 103 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (89), assurance_score_below_0.72 (10), current_regulatory_source_required (9), extraction_ambiguity (90), high_risk_requires_regulatory_or_two_independent_sources (13), no_direct_support (98), proposal_not_staged (2)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. adiponectin ↗

    iuphar-ligand · published 2026-08-25 · retrieved 2026-08-25T22:30:24Z

  2. Association of gestational serum adiponectin with postpartum glycaemic outcomes in GDM: a prospective cohort study. ↗

    pubmed · published 2026-12-01 · retrieved 2026-08-25T22:30:24Z

  3. Role of adiponectin in gestational diabetes mellitus: advances in mechanistic insights and early predictive potential. ↗

    pubmed · published 2026-12-01 · retrieved 2026-08-25T22:30:24Z

  4. The effect of ascorbic acid supplementation on plasma leptin and adiponectin levels: Systematic review ofin vivoandin vitrostudies. ↗

    pubmed · published 2026-12-01 · retrieved 2026-08-25T22:30:24Z

Publication history and provenance

Version 6 · Automated assessment · 2026-08-27T11:48:55Z

ce82134de064242e7de54e0105f52282ca2e4e36a81270520a17d1a5cbf9c2fa